Skip to main content
    N

    Novartis AG ADR (NVS)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $153.75
    +2.63 (+1.74%)

    Market Cap: $287.24B

    Last updated: Oct 27, 2026 at 10:41 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    75%(30/40)
    Avg Surprise
    +2.74%
    Streak
    3 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$2.24
    Range$2.22 - $2.26
    3 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$2.20+1.9%
    60d ago$2.23+0.5%
    30d ago$2.23+0.5%
    7d ago$2.23+0.7%
    Current$2.24
    Revenue Consensus
    $14.6B
    Range$14.3B - $15.1B
    8 analysts
    Period ending Dec 31, 2026
    EPS Consensus$2.38
    Range$2.14 - $2.58
    9 analysts
    Revenue Consensus
    $15.5B
    Range$14.0B - $17.7B
    21 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$2.38---
    Sep 26EST
    		-$2.24---
    Jun 26
    Reported Jul 21
    		$2.41$2.20+9.55%Beat+7.1%
    Mar 26
    Reported Apr 28
    		$1.65$1.65+0.00%Beat-31.8%
    Dec 25
    Reported Feb 4
    		$2.03$2.00+1.50%Beat-11.0%
    Sep 25
    Reported Oct 28
    		$2.25$2.31-2.60%Miss+13.6%
    Sep 25
    Reported Oct 28
    		$2.25$2.26-0.44%Miss+9.2%
    Jun 25
    Reported Jul 17
    		$2.42$2.37+2.11%Beat+22.8%
    Mar 25
    Reported Apr 29
    		$2.28$2.17+5.07%Beat+26.7%
    Dec 24
    Reported Jan 31
    		$1.98$1.76+12.50%Beat+29.4%
    Sep 24
    Reported Oct 29
    		$2.06$1.93+6.74%Beat+18.4%
    Jun 24
    Reported Jul 18
    		$1.97$1.86+5.91%Beat+7.7%
    Mar 24
    Reported Apr 23
    		$1.80$1.68+7.14%Beat+5.3%
    Dec 23
    Reported Jan 31
    		$1.53$1.66-7.83%Miss+0.7%
    Sep 23
    Reported Oct 24
    		$1.74$1.74+0.00%Beat+10.1%
    Jun 23
    Reported Jul 18
    		$1.83$1.76+3.98%Beat+17.3%
    Mar 23
    Reported Apr 25
    		$1.71$1.53+11.76%Beat+17.1%
    Dec 22
    Reported Feb 1
    		$1.52$1.43+6.29%Beat+8.6%
    Sep 22
    Reported Oct 25
    		$1.58$1.62-2.47%Miss-7.6%
    Jun 22
    Reported Jul 19
    		$1.56$1.54+1.30%Beat-6.0%
    Mar 22
    Reported Apr 26
    		$1.46$1.51-3.31%Miss-3.9%
    Dec 21
    Reported Feb 2
    		$1.40$1.41-0.71%Miss+4.5%
    Sep 21
    Reported Oct 26
    		$1.71$1.66+3.01%Beat+12.5%
    Jun 21
    Reported Jul 21
    		$1.66$1.49+11.41%Beat+22.1%
    Mar 21
    Reported Apr 27
    		$1.52$1.62-6.17%Miss-2.6%
    Dec 20
    Reported Jan 26
    		$1.34$1.39-3.60%Miss+1.5%
    Sep 20
    Reported Oct 27
    		$1.52$1.45+4.83%Beat+7.8%
    Jun 20
    Reported Jul 21
    		$1.36$1.33+2.26%Beat+1.5%
    Mar 20
    Reported Apr 28
    		$1.56$1.36+14.71%Beat+28.9%
    Dec 19
    Reported Jan 29
    		$1.32$1.31+0.76%Beat+5.6%
    Sep 19
    Reported Oct 22
    		$1.41$1.35+4.44%Beat+6.8%
    Jun 19
    Reported Jul 18
    		$1.34$1.23+8.94%Beat+3.9%
    Mar 19
    Reported Apr 24
    		$1.21$1.21+0.00%Beat-5.5%
    Dec 18
    Reported Jan 30
    		$1.25$1.30-3.85%Miss+3.3%
    Sep 18
    Reported Oct 18
    		$1.32$1.34-1.49%Miss+2.3%
    Jun 18
    Reported Jul 18
    		$1.29$1.28+0.78%Beat+5.7%
    Mar 18
    Reported Apr 19
    		$1.28$1.27+0.79%Beat+13.3%
    Dec 17
    Reported Jan 24
    		$1.21$1.17+3.42%Beat+8.0%
    Sep 17
    Reported Oct 24
    		$1.29$1.24+4.03%Beat-
    Jun 17
    Reported Jul 18
    		$1.22$1.17+4.27%Beat-
    Mar 17
    Reported Apr 25
    		$1.13$1.10+2.73%Beat-
    Dec 16
    Reported Jan 25
    		$1.12$1.10+1.82%Beat-

    Dividends

    Dividend Metrics

    Forward Yield3.10%
    Forward Annual Dividend$4.77
    Payout Ratio49.68%
    FrequencyAnnual
    Pay MonthsMar

    Growth

    3Y CAGR+6.30%
    5Y CAGR+5.28%
    NVS dividend history and ex-dividend datesRun NVS in the free DRIP calculator

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDA14.99x
    Price/FCF18.60xFCF Yield5.38%
    Profitability
    Profit Margin22.50%Operating Margin34.60%
    ROE30.30%ROIC15.68%
    Financial Health
    Debt/Equity1.13xInterest Coverage12.17x
    Current Ratio0.86xQuick Ratio0.67x
    Trading Statistics
    Beta0.47Avg Volume1.96M
    52-Week High$165.4352-Week Low$117.98

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$150.92
    SMA 20$146.76
    SMA 50$148.17
    SMA 200$150.54
    EMA 10$151.07
    EMA 20$148.75
    EMA 50$148.31
    EMA 200$146.42

    MACD

    Line: 2.20Signal: 1.04Hist: 1.17

    ADX

    ADX: 18.6+DI: 33.6-DI: 25.9

    Aroon & PSAR

    Aroon Up92.0
    Aroon Down40.0
    PSAR$144.00

    Bollinger Bands

    Upper Band$157.15
    Lower Band$136.37
    %B Position1416%(Upper)
    Band Width0.84

    RSI (14-Day)

    Neutral
    61.1

    Momentum Oscillators

    Stoch %K80.2
    Stoch %D88.2
    Williams %R-20.4
    ROC (10d)6.9%
    Momentum9.91
    CCI (20d)99.2
    MFI (14d)64.9

    Volatility Measures

    ATR (14d)$2.98(1.9%)
    StdDev (20d)5.20
    Hist Vol24.9%(Moderate)

    Volume Flow

    VWAP$153.61
    OBV20.3M
    AD Line-914.0M
    CMF (20d)0.026

    Volume Metrics

    Avg Vol (20d)2.0M
    Vol Ratio1.4x
    VWMA (20d)$147.03

    Pivot Points

    R3$161.99
    R2$159.03
    R1$155.08
    Pivot Point$152.12
    S1$148.17
    S2$145.21
    S3$141.26

    Advanced Oscillators

    TSI18.09
    Ultimate Osc61.1
    KST29.77

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total Revenue$14.42B$13.52B$13.33B$14.36B$14.36B$14.84B$13.62B$13.56B$13.17B$12.87B$12.12B$11.78B
    Cost of Revenue$3.68B$3.46B$3.54B$3.54B$3.54B$3.32B$3.23B$3.32B$3.23B$3.17B$3.10B$3.02B
    Gross Profit$10.74B$10.06B$9.79B$10.82B$10.82B$11.51B$10.39B$10.23B$9.94B$9.70B$9.02B$8.75B
    Operating Expenses$6.00B$5.83B$6.27B$6.32B$6.32B$6.65B$5.73B$6.70B$6.31B$5.68B$5.65B$6.17B
    R&D$2.76B$2.74B$2.84B$2.94B$2.94B$2.73B$2.37B$2.84B$2.39B$2.37B$2.42B$2.57B
    SG&A$3.24B$3.14B$3.44B$3.31B$3.31B$3.44B$3.06B$3.50B$3.13B$3.09B$2.84B$3.44B
    Operating Income$4.74B$4.24B$3.52B$4.50B$4.50B$4.86B$4.66B$3.53B$3.63B$4.01B$3.37B$2.58B
    Interest Income$0$0$306.00M$285.00M$0$292.00M$273.00M$200.00M$0$0$6.00M$0
    Interest Expense$462.32M$343.00M$303.98M$281.00M$281.00M$293.64M$270.22M$273.05M$266.88M$245.62M$219.74M$238.87M
    Income Before Tax$4.27B$3.84B$3.22B$4.20B$4.20B$4.53B$4.41B$3.29B$3.38B$3.84B$3.13B$2.38B
    Income Tax Expense$1.01B$683.00M$813.94M$266.00M$266.00M$507.00M$798.00M$465.00M$200.00M$595.00M$441.00M$-261,000,000
    Net Income$3.27B$3.16B$2.41B$3.93B$3.93B$4.04B$3.61B$2.82B$3.19B$3.25B$2.69B$8.48B
    EBITDA$5.94B$5.41B$5.07B$5.84B$5.84B$6.08B$5.83B$5.19B$5.61B$5.25B$4.66B$4.18B
    EBIT$4.74B$4.18B$3.52B$4.48B$4.48B$4.82B$4.68B$3.56B$3.65B$4.09B$3.35B$2.59B
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    When the Old Playbook Fails: Building a Real Defensive Portfolio for the 2026 Oil Shock

    The S&P 500 is already 5% off its January peak. A 10% correction only needs another 5.3% lower and current models put that at 72% probability before year-end 2026. This correction is oil-driven...

    Glenn Ford
    •
    3/15/26
    •
    463
    market correction, defensive stocks
    Also mentions:
    NVSPEGMDTAEM

    Incyte’s Earnings: Strong Growth Amid Market Overlook

    INCY generates $1.17B annual FCF with 93% gross margins and zero leverage, yet trades at 15.6x earnings. Reverse-DCF implies ~0% growth priced in. Quality Score 100/100 with ROIC 25.4%, Piotroski 8/9, interest coverage 702x...

    Glenn Ford
    •
    2/11/26
    •
    154
    Biotech, Healthcare Stocks
    Also mentions:
    NVSLLYREGNGILD

    Government Contracts

    Gov Obligations (TTM)
    $29.09M
    Gov Obligations / Revenue
    0.1%
    Obligations YoY
    42.0%
    Active Awards
    78
    New Awards (TTM)
    50
    Avg Remaining Term
    3.2 mo

    Top agency: Department of Veterans Affairs at 85.1% of trailing twelve month obligations across 3 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    36C24826F0082Department of Veterans AffairsDepartment of Veterans Affairs$4.73MFeb 24, 2026
    36C25726N0205Department of Veterans AffairsDepartment of Veterans Affairs$4.16MFeb 7, 2026
    36C26126F0007Department of Veterans AffairsDepartment of Veterans Affairs$3.99MOct 1, 2025
    36C26226N0112Department of Veterans AffairsDepartment of Veterans Affairs$3.91MNov 1, 2025
    W81K0025FA195Department of DefenseDepartment of the Army$3.23MOct 1, 2025
    36C24926N0263Department of Veterans AffairsDepartment of Veterans Affairs$2.91MDec 20, 2025
    36C25026N0310Department of Veterans AffairsDepartment of Veterans Affairs$2.42MFeb 1, 2026
    36C24426F0063Department of Veterans AffairsDepartment of Veterans Affairs$1.98MJan 1, 2026
    36C26126F0017Department of Veterans AffairsDepartment of Veterans Affairs$1.63MOct 1, 2025
    36C25526N0132Department of Veterans AffairsDepartment of Veterans Affairs$1.20MFeb 17, 2026

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Form 6-K NOVARTIS AG For: Sep 30

    Novartis AG filed a Form 6-K with the U.S. Securities and Exchange Commission on October 27, 2026, for the period ending September 30. This report incorporates by reference certain financial information...

    StreetInsider•10/27/26•Neutral

    Novartis raises profit outlook after strong Q3 sales growth; shares rise

    Novartis AG raised its full-year core operating income outlook after reporting strong third-quarter sales growth and margin expansion...

    Investing.com•10/27/26•Neutral

    Novartis AG's Q3 revenue rose 4% year-on-year, while impairments in long-term pipeline assets weighed on net profit.

    Novartis AG reported a 4% year-on-year increase in Q3 revenue. Despite the revenue growth, the company's net profit was negatively impacted by impairments in its long-term pipeline assets.

    Moomoo•10/27/26•Somewhat-Bearish

    Novartis Remibrutinib Cuts MS Relapses in Phase III, Eyes $4B Opportunity

    Novartis announced positive Phase III results for remibrutinib in relapsing multiple sclerosis, showing significant reductions in relapse rates and MRI lesion activity compared to teriflunomide. The company plans to file...

    Yahoo Finance•10/23/26•Bullish

    Novartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib

    Novartis's oral multiple sclerosis drug, remibrutinib, showed a weaker reduction in annualized relapse rates than analysts expected...

    Reuters•10/23/26•Somewhat-Bearish

    NVS Valuation and Fair Value

    Forward P/E
    14.1x
    EV/EBITDA
    15.0x
    P/FCF
    18.6x
    PEG
    3.2x
    P/B
    7.1x
    See GNG's fair value

    NVS Profitability: Margins, ROIC and FCF

    Gross margin
    74.4%
    Operating margin
    34.6%
    Net margin
    22.5%
    ROIC
    15.7%
    ROE
    30.3%
    FCF margin
    28.4%
    FCF yield
    5.4%

    NVS Competitors

    CompanyTicker
    Merck & Company IncMRK
    AstraZeneca PLCAZN
    UnitedHealth Group IncorporatedUNH
    Thermo Fisher Scientific IncTMO
    AbbVie IncABBV
    Amgen IncAMGN
    Johnson & JohnsonJNJ
    Gilead Sciences IncGILD

    Sector: Healthcare

    NVS Analyst Ratings

    Consensus
    Buy
    Analysts
    12
    Strong Buy
    3
    Buy
    2
    Hold
    6
    Sell
    1
    Strong Sell
    0

    NVS Bull Case vs Bear Case

    Bull case

    • NVS earns a 15.7% return on invested capital.
    • NVS converts 28.4% of revenue into free cash flow.
    • NVS has a 22.5% net profit margin.

    NVS Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    3.5%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $2.24
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 0 down

    NVS Dividend

    Forward yield
    3.1%
    Payout ratio
    49.7%
    3Y DPS growth
    6.3%
    5Y DPS growth
    5.3%
    Pay months
    Mar
    NVS dividend history

    Frequently Asked Questions About NVS

    What is NVS's current dividend yield?

    Novartis AG ADR (NVS) has a forward dividend yield of 3.10%.

    Does NVS pay dividends?

    Yes, Novartis AG ADR pays dividends with a forward dividend yield of 3.10%.

    What is NVS's market cap?

    Novartis AG ADR (NVS) has a market capitalization of $287.24B with a current stock price of $153.75.

    Related stocks

    Sector: Healthcare

    All stocks starting with N

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In